We evaluated the efficacy of physiotherapy, occupational therapy, and speech and language therapy in Parkinson's disease by synthesizing six Cochrane systematic reviews. All randomised, controlled trials examining the efficacy of a paramedical therapy versus control intervention and all those comparing the efficacy of two forms of active therapy in Parkinson's disease were included. Trials were identified by searching biomedical databases, reference lists, hand searching, and contacting investigators. The main outcome measures were quality of life, speech intelligibility, activities of daily living, and individual measures of motor and speech impairment. We identified 16 physiotherapy randomised controlled trials (399 patients), two occupational therapy trials (84 patients), and five speech and language therapy for dysarthria trials (154 patients).
Anecdotal evidence from patients, health professionals, and the Parkinson's Disease Society strongly supports the use of paramedical therapies in the comprehensive management of Parkinson's disease in addition to optimal medical and surgical treatment. These paramedical therapies include physiotherapy, occupational therapy, and speech and language therapy. Despite this support for paramedical therapies, 1 several surveys have demonstrated that only 3 to 29% of patients with Parkinson's disease have seen a paramedical therapist. [2] [3] [4] [5] This low rate of referral may partly reflect clinicians' belief that there is little evidence for using such therapy, although the under-provision of such services in the United Kingdom may be an additional factor. A systematic review of the existing data is required to clarify the evidence about the role of paramedical therapies in Parkinson's disease.
Paramedical therapists treating people with Parkinson's disease provide appropriate exercises, aids, education, and advice that aim to help patients to better understand and cope with their disease. The core areas of physiotherapy relate to gait, balance, posture, and transfers. 6 Occupational therapists use therapeutic techniques and provide aids and adaptations to allow normal work, self-care, and leisure activities to continue. Speech and language therapists treat patients with specific exercises and advice about speech and swallowing.
This review synthesises six systematic reviews of paramedical therapies in Parkinson's disease published in the Cochrane Library by the current authors. [7] [8] [9] [10] [11] [12] It examines randomised controlled trials comparing each paramedical therapy with control intervention or no therapy and those comparing two forms of active therapy.
PATIENTS AND METHODS

Criteria for Considering Trials for Review
We included only randomised or quasirandomised controlled trials that evaluated speech and language therapy for dysarthria, physiotherapy, and occupational therapy (see Appendix). We also included studies that evaluated the nonpharmacological treatment of dysphagia, but excluded studies for which the therapist's advice was to insert a nasogastric or percutaneous gastrostomy tube. Participants in the trials were patients with Parkinson's disease (as defined by the authors of the trials), of any disease duration, of all ages, and on any form of drug therapy. We did not select trials by duration of treatment, and we accepted trial reports in any language.
Search Strategy
We identified trials by searching general biomedical databases (Medline, EMBase, CINAHL, and ISI-SCI), rehabilitation databases (AMED, Mantis, Rehabdata, and Rehadat), English-language databases of foreign language research and third world publications (Gerolit, Pascal, LILACS, MedCarib, JICST-EPlus, AIM), grey literature databases (IMEMR; SIGLE, ISI-ISTP, DISSABS, Conference Papers Index, and Aslib Index to Theses), trials registers (the Cochrane Controlled Trials Register, the CentreWatch Clinical Trials listing service, the metaRegister of Controlled Trials, ClinicalTrials.gov, CRISP, PEDro, NIDRR, NRR), and the reference lists of identified trials and other reviews. Our search strategy was based on that of the Cochrane Movement Disorders Group, which essentially cross-referenced as MeSH headings and text words: Parkinson's disease and all its derivations, with rehabilitation, physical therapy, physiotherapy, exercise, occupational therapy, speech, voice, language, dysarthria, swallow, and dysphagia.
Methods
Two authors, per Cochrane review, independently extracted the data and settled differences by discussion. Where possible, we asked the original investigators for additional data or clarification of methods. Each trial was compared with a standard set of quality criteria to examine points where its design may have introduced bias (Table 1) . These criteria are defined in the Appendix.
RESULTS
Description of the Trials
Twenty-three randomised controlled trials examined paramedical therapies for 637 Parkinson's disease patients. We excluded two trials: one for incomplete randomisation of the trial participants, 13 and the other because we determined that osteopathic manipulation was not part of mainstream physiotherapy practice.
14 The included trials had methodological flaws that could have introduced bias, used heterogeneous therapy methods, and measured many different outcomes; therefore, we could not summarise the results quantitatively by metaanalysis (Tables 2 and 3 ). Consequently a systematic qualitative appraisal was performed.
Methodological Quality of the Trials
The trial methods varied in quality (Table 1 and Appendix 1) and all trials had at least one methodological flaw that could have introduced bias. No trial examined had the combination of an adequate method of randomisation, adequate concealment of the allocation, had blinded their assessors, and had an adequate placebo. These four quality items are generally regarded as having the greatest impact on the validity of a trial's results. For example, only seven trials truly randomised allocation to treatment groups, and of these, only four adequately concealed allocation. Fourteen of the 16 trials with an inactive control arm failed to use a placebo intervention. We defined an adequate placebo therapy intervention as being one that provided an inactive treatment to patients for a similar period of time and in a similar setting as the active therapy arm. Ten of the 23 trials either failed to examine baseline differences or were unbalanced due to small sample sizes. Although the trials examined many outcome measures, there was no consensus on which were the most appropriate. Poor presentation and inadequate statistical analysis often hampered interpretation of the results (Tables 4 and 5 ). Physiotherapy Eleven trials compared physiotherapy with placebo or no treatment in 280 patients. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The physiotherapy techniques, duration, and location in the trials varied considerably (Table 1) . Four trials had interventions from other therapists or had components of their protocol that could be described as occupational therapy. 16, 17, 20, 21, 25 However, the occupational therapy components were poorly defined, and the aims and outcomes of the trials were mostly centred around mobility.
A summary of the results is given in Tables 4 and 5 . Only Chandler and Plant 16 measured quality of life, but they did not give a full statistical analysis of their results. Patti and colleagues 25 measured activities of daily living on several scales after intensive inpatient physiotherapy. All of these scales showed improvements that were maintained for 5 months. The trials measured several individual motor impairments, but only two outcomes were measured in more than one trial: walking velocity in five trials 16, 22, [25] [26] [27] and stride length in three trials 22, 25, 27 (Table 4) . Walking velocity increased significantly in two trials, by 50 to 64%, 25, 27 but this improvement was not seen in the other two trials. 16, 26 Stride length also improved significantly in two trials by 23% in both. 25, 27 No data for walking velocity or stride length was available in one trial. 22 Seven trials compared two forms of physiotherapy in 142 patients (see Table 2 ). 22, [27] [28] [29] [30] [31] [32] [33] The majority of outcomes measured were reported to have improved after the novel therapy under investigation (Table 5) . One of the techniques used is cueing. This is the prompting of a movement by an external auditory or visual cue such as LSVT > respiration (P not stated) [39] [40] [41] [42] [43] [44] Speech intelligibility NA LSVT > respiration (carers assessment) (P not stated) [39] [40] [41] [42] [43] [44] 51 LSVT ‫ס‬ respiration (patient assessment) [39] [40] [41] [42] [43] [44] 51 Activities of daily living Strength & balance > balance (P < 0.05) 29 NA Cued ‫ס‬ standard 28 Behavioural ‫ס‬ standard 30, 31 Karate ‫ס‬ standard 50 Impairments: summary scores Cued > standard (P < 0.02) 28 NA Behavioural > standard (P ‫ס‬ 0.01) 30, 31 Impairments: walking velocity Walking + auditory cues > walking (P ‫ס‬ 0.03) 27 NA Impairments: subjective speech loudness NA LSVT ‫ס‬ Respiration [39] [40] [41] [42] [43] [44] The authors of these studies defined the statistical significance of data when compared between the two therapy groups. The equal sign refers to no statistically significant difference having been found.
LSVT, Lee Silverman Voice Therapy; NA, not appropriate. 27, 28 In both of these studies, the addition of cueing techniques improved the efficacy of the physiotherapy (Table 5) .
Occupational Therapy
Two trials examined occupational therapy in 84 patients (Table 2) . 34, 35 These differed markedly in their methodology. Gauthier and associates 35 compared group occupational therapy with an untreated control group, whereas Fiorani and coworkers 34 compared group occupational therapy and physiotherapy with individualised physiotherapy. The method of occupational therapy by Fiorani and colleagues 34 included game playing and basketry as major components of the therapy. Neither trial compared data statistically between groups (Table 4) .
Speech and Language Therapy for Dysarthria
Three trials compared speech and language therapy with placebo in 63 Parkinsonian patients with dysarthria. [36] [37] [38] The methods differed considerably (Table 2) . No trial measured quality of life, speech intelligibility, or activities of daily living affected by poor communication (Table 4) . In two trials, 36, 37 loudness of speech increased significantly by 5-12 dB (8-17%) from a mean baseline loudness of 60 dB. Ramig and associates showed that this improvement was maintained after 6 months. 37 Two trials compared two methods of speech and language therapy in 71 patients. [39] [40] [41] [42] [43] [44] [45] [46] Ramig and coworkers measured aspects of quality of life affected by speech with the communication subsection of the Sickness Impact Profile. The communication subsection score improved by a significant 61% (baseline score of 29) immediately after Lee Silverman Voice Therapy (LSVT) compared with respiration therapy; however, this improvement was not maintained after 12 months (Table 5) . Both trials measured intelligibility on 100-point visual analogue scales, but only Ramig and colleagues compared the therapy groups statistically. [39] [40] [41] [42] [43] [44] Although patients noticed no difference in outcome between the two therapy modes, their carers found them more intelligible after LSVT. Ramig and associates measured several individual measures of speech quality up to 2 years after therapy.
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Speech and Language Therapy for Dysphagia
No trials examined the efficacy of nonpharmacological swallowing therapy for dysphagia in Parkinson's disease.
DISCUSSION
Outcome Measures
Many of the trials outlined in this review have concentrated on specific impairment outcomes such as stride length or vocal loudness. However, it should be noted that, in a recent international survey of people with Parkinson's disease, the physical aspects of the disease only accounted for 17% of the patients' quality of life. 47 It is increasingly recognised that, although improvement in a specific impairment is easily measured, it may have little benefit for the patient in their life.
Physiotherapy
The trials of physiotherapy showed some limited evidence of efficacy, particularly with specific gait characteristics such as walking velocity and stride length. Activities of daily living improved in the one trial in which they were measured. Quality of life did not improve in the one trial in which it was measured, and economic analysis was not undertaken in any of the trials.
The trials used a wide variety of therapy methods, which leads to difficulty in determining the type of physiotherapy to be tested in a large multicentre trial. The Physiotherapy Evaluation Project (PEP) examined current physiotherapy practice using a Delphi technique and developed a consensus approach for physiotherapy in Parkinson's disease. 6 Practice guidelines have recently been completed by the same group (online.unn.ac.uk/ faculties/hswe/research/rehab/Guidelines/intro.htm). A large, randomised, controlled trial is being designed to examine the effectiveness of physiotherapy using these guidelines.
Occupational Therapy
The two trials of occupational therapy produced results of little value due to problems in the design of the trials that could have led to bias, the small numbers of patients examined, and the marked heterogeneity of the two methods used. Also, both trials examined group occupational therapy; this strategy is unlikely to address an individual's specific occupational aims and needs. We are conducting a Delphi survey to develop a consensus on core occupational therapy practice for Parkinson's disease in the United Kingdom. The consensus document will inform the development of practice guidelines and the design of a large, multicentre, randomised, controlled trial.
Speech and Language Therapy
The results from the trials of speech and language therapy are encouraging, as the improvements measured do appear to be clinically significant. However, improved intelligibility must be the primary aim in these trials, and this was not measured in the placebocontrolled trials. It should also be noted that much of the data came from two trials that examined the same unique treatment (Lee Silverman Voice Therapy). 37, [39] [40] [41] [42] [43] [44] Again, the lack of firm data suggests that a large, multicentre, randomised, controlled trial is required. Although the Royal College of Speech and Language Therapists has published consensus guidelines for the therapy of dysarthria, these guidelines are not specific for the treatment of Parkinson's disease and do not contain details of style, duration, or intensity of therapy.
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Future Trial Design
These reviews emphasise the many methodological shortcomings in the 23 trials of paramedical therapies in Parkinson's patients and prompt us to make recommendations for conducting future paramedical therapy trials in Parkinson's disease and other conditions ( Table 6 ). Trials of rehabilitation therapies differ from standard drug trials in that neither the therapist nor the patient can be blinded as to which treatment arm of the trial they are assigned to. Although this inherent lack of blinding can lead to the introduction of bias, efforts should still be made to provide an adequate placebo arm. People with Parkinson's disease are often socially isolated and involvement in the active therapy arm of a trial might well reduce this sufficiently to improve the patient's perception of their well-being. A valid placebo therapy would have the patients visit the outpatient department as often and have someone spend a similar period of time with them. However, it is recognised that a placebo therapy may be impractical to apply in large multicentre trials and that an untreated "best medical practice" group would represent a more practicable, although less adequate comparator. This method would lead to difficulties in estimating the size of improvement due to therapy because of placebo effect, which is estimated at between 10 to 30% in Parkinson's disease; however, this design may be more reflective of current therapy provision and practice.
We recognise that the poor quality of reporting of some trials may be due to them being published before the adoption of the CONSORT reporting guidelines in 1996. 49 Future reports of trials must conform to these guidelines so that their results can be fairly assessed. Publication bias arises from the tendency for trials with inconclusive or negative results not to be published in peer-reviewed journals. Only one trial of the 23 reported here found a negative result. 20, 21 Many trials that found negative or equivocal results may not have been published in peer-reviewed journals. We are aware of at least two unpublished negative trials whose investigators have declined to provide data for analysis in the Cochrane reviews.
Implications
Because of the methodological flaws, the small number of patients examined, and the possibility of publication bias, the trials provide insufficient evidence to support or refute the efficacy of these therapies in Parkinson's disease. We emphasise that the current lack of evidence for efficacy of these treatments does not suggest a lack of effect; rather that further work is required. Large, pragmatic, randomised, controlled trials are needed to assess the effectiveness of paramedical therapies in Parkinson's disease.
